BioSpace News Archive

Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 9:20 a.m. EST.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that its New Drug Application for poziotinib has been accepted for review by the U.S. Food and Drug Administration.

Data from several new studies presented this week at the American Heart Association International Stroke Conference (ISC) further validates the best-in-class sensitivity and specificity of Viz.ai’s intelligent care coordination platform for stroke in real world settings across multiple commercial modules.

Sensei Biotherapeutics, Inc., an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, announced that company management will participate in Citi’s 2022 Immuno-Oncology Summit.

Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021 and provided financial guidance for 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from its Phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the grant of inducement awards outside of the Company’s 2019 Stock Incentive Plan to Amy Winnen, the Company’s newly appointed Vice President, Head of Market Value, Access and Policy.

Spectral Medical Inc. provided a clinical trial update on Tigris, a follow on study designed to build on knowledge gained from the earlier EUPHRATES trial, evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Keros Therapeutics, Inc. announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D. will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18th at 9:20 am ET.